**QUEEN'S
UNIVERSITY
BELFAST**

Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate 1 infection of well-differentiated primary pediatric bronchial epithelial cell cultures

Broadbent, L., Guo Parke, H., Ferguson, L., Millar, A., Shields, M., Detalle, L., & Power, U. (2020). Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate 1 infection of well-differentiated primary pediatric bronchial epithelial cell cultures. *Antimicrobial Agents and Chemotherapy*, 64(2), [e02034-19]. <https://doi.org/10.1128/AAC.02034-19>

Published in:
Antimicrobial Agents and Chemotherapy

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2019 American Society for Microbiology. This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate
infection of well-differentiated primary pediatric bronchial epithelial cell cultures

Lindsay Broadbent^a, Hong Guo Parke^a, Lyndsey J. Ferguson^a, Andrena Miller^a, Michael D.
Shields^{a,b}, Laurent Detalle^{c*}, Ultan F. Power^{a#}.

^aWellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast,
United Kingdom

^bRoyal Belfast Hospital for Sick Children, Belfast Health & Social Care Trust, Belfast, United
Kingdom

^cAblynx nv, Belgium

*Current affiliation: UCB Biopharma SPRL
[Chemin du Foriest B-1420 Braine-l'Alleud, Belgium](#)

Running Head: Efficacy of ALX-0171 against two RSV strains

Address correspondence to Professor Ultan Power u.power@qub.ac.uk

Abstract

Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections in young infants. There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific Nanobody®, ALX-0171. To characterise the therapeutic potential of ALX-0171 we exploited our well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC)/RSV infection model, which replicates several hallmarks of RSV disease *in vivo*. Using 2 clinical isolates (BT2a; Memphis 37), we compared the therapeutic potential of ALX-0171 with palivizumab, which is currently prescribed for RSV prophylaxis in high-risk infants. ALX-0171 treatment (900 nM) at 24 h post-infection reduced apically released RSV titers to near or below the limit of detection within 24 h for both strains. Progressively lower doses resulted in concomitantly diminished RSV neutralisation. ALX-0171 was approximately 3 fold more potent in this therapeutic RSV/WD-PBEC model than palivizumab (mean IC_{50} = 346.9-363.6 nM and 1048-1090 nM for ALX-0171 and palivizumab, respectively), irrespective of the clinical isolate. When viral genomic copies (GC) were measured by RT-qPCR, the therapeutic effect was considerably less and GCs were only moderately reduced (0.62 – 1.28 $\log_{10}$ copies/mL) by ALX-0171 treatment at 300 and 900 nM. Similar findings were evident for palivizumab. Therefore, ALX-0171 was very potent at neutralising RSV released from apical surfaces but only had a limited impact on virus replication. The data indicate a clear disparity between viable virus neutralisation and GC viral load, the latter of which does not discriminate between viable and neutralised RSV. This study validates the RSV/WD-PBEC model for the pre-clinical evaluation of RSV antivirals.

43

44 **Introduction**

45 Respiratory syncytial virus (RSV) is a member of the *Pneumoviridae* family, *Orthopneumovirus*
46 genus (1). It is the leading cause of severe lower respiratory tract infections (LRTI) in infants
47 worldwide (2, 3) with an estimated 33.8 million LRTI cases yearly. RSV accounts for
48 approximately 3.4 million hospitalizations and up to 199,000 deaths worldwide, predominantly
49 in developing countries (4). Economic burden and childhood morbidity and mortality rates
50 associated with RSV are, in many countries, comparable to influenza(5).

51 Severe RSV infection is associated with an increase in mucus production and a decrease in the
52 number of ciliated cells in the airway epithelium. There is a large influx of immune cells to the
53 airways, predominantly neutrophils but also lymphocytes and macrophages (6). The cellular
54 infiltrate, together with mucus and sloughed epithelial cells, causes lumen obstruction and
55 inflammation of the airways. Associated with mucus plug formation and bronchiole occlusion,
56 bronchiolitis is therefore more severe in smaller airways, such as those of young or preterm
57 infants (7). Accordingly, 66% of RSV-related hospitalizations are in children <6 months old (8).
58 Risk factors associated with the development of severe RSV-LRTI in infants include:
59 prematurity, bronchopulmonary dysplasia, congenital lung or heart conditions, male gender, age
60 ≤ 6 months, neuromuscular disorders, and immunodeficiency (9). However, the majority of
61 patients that require hospitalization due to severe RSV-related disease have no underlying health
62 conditions that constitute a risk factor (3). There is mounting evidence to suggest that a severe
63 RSV infection in early life is associated with the development of wheeze and subsequently
64 asthma(10).

RSV infection remains a major unmet medical treatment need. Other than the antiviral ribavirin, there is no licensed RSV vaccine or therapeutic, despite the considerable medical importance of this virus. Palivizumab, a neutralizing monoclonal antibody that recognizes a conserved epitope in the viral fusion surface glycoprotein (RSV F site II)(11), is administered prophylactically to high risk infants, e.g., chronic lung disease of prematurity, congenital heart disease or premature birth (typically limited to those less than 29 weeks gestational age for cost/benefit reasons). This is an expensive approach, costing \$6,000 to \$20,000 per patient for 1 RSV season(12). In addition to price, as indicated above, a major limitation of this approach is that the majority of infants hospitalized with RSV do not fall into these high-risk categories. Palivizumab was assessed as a therapeutic treatment in patients hospitalised with RSV but failed to demonstrate a reduction in viral titers from nasal aspirates or disease severity(13). Therefore, understanding how RSV causes disease in humans and development of therapeutics remains an important medical objective.

One potential limitation to RSV antivirals being effective is that the viral load may have peaked by the time infants are hospitalized. However, a study of RSV clearance in hospitalized children demonstrated that higher viral titers at day 3 of hospitalization were not associated with risk factors such as weight, gestational age, sex, or age at time of admission but were associated with the requirement for intensive care and respiratory failure, indicating a potential therapeutic window even in hospitalized infants (14). Osteltamivir (Tamiflu), an antiviral against influenza virus, demonstrates the importance of the time of administration following infection for effective treatment; it is effective at reducing the length of illness in patients hospitalised with influenza when administered within 48 h of symptom onset in clinically confirmed cases of influenza(15). When administered after this time, however, osteltamivir failed to have any effect on virus titers,

disease severity or illness duration(16).

The majority of RSV pathogenesis, antiviral and prophylaxis studies have been performed in animal models or continuous cell lines, neither of which are optimal. Animal models, especially mice, are semi-permissive for RSV replication and do not exhibit high viral titers or pulmonary pathology associated with RSV in infants unless very high inocula are employed (17–19). Continuous cell lines, e.g. HEp-2 and A549 cells, are poorly representative of the complexities of cell interactions in the human lung. The development of the well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC) culture model has provided an authentic surrogate facilitating the elucidation of mechanisms of RSV pathogenesis in pediatric airways (20, 21), and thereby, the study of RSV-specific antivirals. WD-PBECs reproduce hallmarks of RSV infection *in vivo* and can be infected for prolonged experiments with extensive damage to the cultures(22). Several studies have demonstrated RSV neutralisation in human airway epithelial cells (HAE) that were not evident in experiments using continuous cell lines such as HeLa or HEp-2(23, 24).

There are several RSV therapeutics currently in development including entry inhibitors and nucleoside analogues(25). One potential RSV therapeutic has been developed by Ablynx, , ALX-0171, which is a trivalent non-half-life extended Nanobody® that specifically binds to RSV F site II. ALX-0171 is composed of 3 heavy chain variable region (VHH) domains, providing strong binding to RSV and it potently neutralises infectious virions (26). The neutralizing and therapeutic ability of ALX-0171 against RSV was previously demonstrated in the neonatal lamb RSV-infection model using the RSV strain Memphis 37 (27). In this current study, we exploited our well-differentiated pediatric primary bronchial epithelial cell (WD-PBEC) culture model of RSV infection to assess the relative ALX-0171 IC₅₀ for the two RSV clinical strains, BT2a and Memphis 37, in comparison to palivizumab. We also aimed to establish whether any adjustment

in the targeted lung lining fluid concentration, as determined in the RSV lamb model, is needed based on strain sensitivity differences.

Results

There was a clear dose-effect of ALX-0171 treatment on RSV BT2a and Memphis 37 growth kinetics. RSV BT2a titers diminished dramatically by 24 h of treatment with 900 nM ALX-0171 with a 4.74 log₁₀ reduction in mean virus titers (Figure 1A). The virus was almost completely neutralized by this time under these conditions and virus neutralization was maintained for the duration of the experiment. Treatment with 300 nM also resulted in reductions in apically-released RSV BT2a, with >2 log₁₀ reduction in mean virus titers evident at 144 hpi relative to buffer-treated RSV BT2a-infected control cultures. A less marked reduction in mean RSV BT2a titers was observed following treatment with 100 nM relative to buffer-treated controls.

Substantial reductions were also evident in RSV Memphis 37 titers by 24 h of treatment with 900 nM ALX-0171, with a 4.2 log₁₀ reduction in mean virus titers, although low virus titers were continually detectable in these cultures until 144 hpi (Figure 1B). Lower, but nonetheless substantial, reductions in RSV Memphis 37 titers were also evident following treatment with 300 nM ALX-0171, whereas treatment with 100 nM did not result in substantially reduced viral titers. In contrast, treatment with ALX-0171 concentrations <100 nM did not influence growth kinetics of either RSV strain relative to buffer-treated control cultures under these experimental conditions.

Unlike ALX-0171, infectious RSV BT2a was detected following treatment with all palivizumab concentrations. However, there was a clear dose-effect on virus titers following palivizumab

treatment of RSV BT2a-infected WD-PBEC cultures. Treatment with 900 nM palivizumab resulted in $>2 \log_{10}$ reduction in viral titers. Treatment with 300 or 100 nM palivizumab also resulted in substantial but lower reductions in viral titers compared to buffer-treated controls (Figure 2A). However, treatment with 33, 11 or 4 nM palivizumab had no effect on the growth kinetics of RSV BT2a.

Similar results were also observed in RSV Memphis 37 titers following treatment with palivizumab. Treatment with either 900 or 300 nM palivizumab resulted in substantial reductions in viral titers (Figure 2B). However, only slight reductions in mean Memphis 37 titers were evident following treatment with 100 nM palivizumab. Treatment with <100 nM palivizumab did not alter the growth kinetics of RSV Memphis 37 relative to the buffer control.

Treatment with 900 nM, 300 nM or 100 nM of either ALX-0171 or palivizumab resulted in substantial reductions in RSV BT2a titers. At the highest concentration tested (900 nM), ALX-0171 appeared to be considerably more potent than palivizumab, reducing the viral titers to the limit of detection (Figure 3A). The two highest concentrations of ALX-0171 (900 nM and 300 nM) and only the highest concentration for palivizumab substantially reduced the viral titers of RSV Memphis 37 compared to buffer-treated controls. However, treatment with ALX-0171 resulted in greater reductions in viral growth kinetics compared to treatment with palivizumab at equimolar concentrations, except for treatment with 100 nM of ALX-0171 or palivizumab, which showed similar viral titers at each time point (Figure 3B).

The IC_{50} for each treatment against each virus over the time course of the experiment was calculated (Table 1). The palivizumab IC_{50} (1090 nM) was significantly higher than the IC_{50} of ALX-0171 (363.6 nM) against Memphis 37. Similarly, the IC_{50} of palivizumab (1048 nM)

against BT2a was also significantly higher than that of ALX-0171 (346.9 nM). The IC_{50} calculated from the area under the curves was not significantly different for either ALX-0171 ((p-value = 0.751) or palivizumab (p-value = 0.858) against the two RSV strains, indicating that both viruses had comparable sensitivities to neutralisation in the WD-PBEC culture model.

A trend towards reduction in RSV BT2a viral loads, as determined by RT-qPCR, was evident following treatment with both ALX-0171 and palivizumab. At 144 hpi, ALX-0171 900 and 300 nM doses reduced mean viral loads by 0.8 $\log_{10}$ genome copies (GC)/mL and 1.3 $\log_{10}$ GC/mL, respectively, versus buffer-treated cultures (Figure 4A). At the same timepoint and for the same doses, palivizumab reduced mean viral loads by 0.3 and 0.8 $\log_{10}$ GC/mL versus buffer-treated cultures, respectively. Similarly, reduced viral loads were observed with both ALX-0171 and palivizumab treatment of Memphis 37-infected WD-PBEC cultures. At 144 hpi, 900 and 300 nM ALX-0171 reduced mean viral loads by 0.62 $\log_{10}$ and 0.76 $\log_{10}$ GC/mL, respectively, versus the buffer-treated cultures (Figure 4B). At the same time point and for the same doses, palivizumab reduced mean viral loads by 0.27 and 0.57 $\log_{10}$ GC/mL, respectively, versus buffer-treated control cultures.

Discussion

The aims of this study were two-fold: to assess the efficacy of ALX-0171 as an anti-RSV therapeutic; and to evaluate the WD-PBEC model for use in pre-clinical studies. Despite extensive research into RSV pathogenesis and mechanisms of disease, vaccines and treatments have remained elusive. Ablynx nv has developed ALX-0171 to address the need for a RSV treatment option. In this study we used our RSV/WD-PBEC model to assess the therapeutic

potential of ALX-0171 or palivizumab to neutralise two different clinical strains of RSV. Palivizumab is the only licensed neutralising anti-RSV monoclonal antibody. It is administered prophylactically and reserved for infants deemed at high risk of severe RSV infection, in large part because of its high cost. However, the majority of children hospitalised due to severe RSV infection are not classified as high-risk and, as such, do not receive palivizumab prophylaxis. A therapeutic intervention that can be administered after the onset of symptoms would reduce the huge economic burden of RSV and potentially reduce the number and/or duration of hospitalisations.

Growth kinetics for both RSV Memphis 37 and BT2a followed a similar pattern in the WD-PBECs. Both strains reached similar peak viral titers between 72 and 96 hpi. RSV BT2a and Memphis 37 demonstrated similar susceptibilities to neutralisation by ALX-0171 or palivizumab. The highest concentration of ALX-0171 (900 nM) reduced viral titers to near or below the limit of detection by 24 h post-treatment ($\sim 5 \log_{10}$ reduction), whereas palivizumab treatment at the same concentration was less effective ($\sim 3 \log_{10}$ reduction). These differences were reflected in the respective IC_{50} values for both molecules.

The RT-qPCR data demonstrated that ALX-0171 or palivizumab treatment resulted in a trend toward reduced viral replication for both RSV BT2a and Memphis 37 but this did not reach significance. However, the differences were much less marked than the $TCID_{50}$ data. When the $TCID_{50}$ and RT-qPCR data were considered together they suggested that both ALX-0171 and palivizumab treatment resulted in efficient neutralization of RSV released from the WD-PBEC cultures ($TCID_{50}$ results) but had a limited effect on intracellular virus replication. Interestingly, a similar effect was seen following motavizumab administration to infants hospitalised with RSV; a significant reduction in infectious viral titers was reported coincident with a much lower

reduction in virus copy numbers(28). However, the RT-qPCR assay does not distinguish between released virus that was neutralized and virus that remained infectious, thereby masking the effect of treatment. Similarly, it was shown that the natural rate of viral load decline is less steep when using a RT-qPCR method than when using quantitative infectivity culture and that this can confound antiviral efficacy determination of test compounds targeting RSV replication(29).

The respiratory system of human infants and young lambs have similarities, suggesting that lambs provide interesting models for asthma, drug delivery, lung development and vaccine efficacy studies(30). A neonatal lamb-RSV Memphis 37 model was also used to assess the efficacy of ALX-0171. There are several similarities in the results from the neonatal lamb model and the WD-PBEC model. Both models showed peak viral titers between 72 to 96 hpi. ALX-0171-treated lambs also demonstrated reduced clinical signs of disease and diminished lung pathology. Importantly, similar IC_{50} values for inhibition of viral growth kinetics following ALX-0171 treatment were obtained from WD-PBECs and neonatal lambs.

The highest Memphis 37 titers reached in the lamb model and the WD-PBEC model in the current study were $4.83 \log_{10}$ FFU/mL(27) and $7.05 \log_{10}$ TCID₅₀/mL for the buffer-treated cultures, respectively. As such, RSV evidently reached much higher peak viral titers in the WD-PBEC model compared with the lamb model under these experimental conditions. However, RSV infectivity titers in nasal and/or tracheal aspirates from hospitalised infants were reported to range from $\sim 10^1$ to $\sim 10^7$ pfu/mL, suggesting that virus replication in both models may reflect virus growth kinetics in infants(14). In the lamb model viral titers in the lungs were markedly reduced by day 8. However, persistent RSV infection was reported in a WD-PBEC model over a 3 month period, with limited damage to the culture(31). Despite these differences, both the WD-PBEC culture model and neonatal lamb model provided similar IC_{50} values. As the reduction in

223 viral titers was similar in the neonatal lamb model and the WD-PBEC model, and the lambs
224 treated with ALX-0171 had lower clinical severity scores, it is possible that the titer reductions
225 observed in WD-PBECs following ALX-0171 treatment might be predictive of lower clinical
226 severity scores in infants. However, this evidently remains to be confirmed. Nonetheless, our
227 data suggest that our RSV/WD-PBEC model may be of interest in helping to bridge the gap
228 between poorly-predictive pre-clinical animal models and clinical trials to further support the
229 rationale for developing promising RSV therapeutics.

230 Although palivizumab is licensed for use as a prophylactic, when tested therapeutically it
231 resulted in modest but significant reductions in viral growth kinetics from tracheal aspirates.
232 However, these viral reductions were insufficient to reduce clinical severity in patients
233 hospitalised with RSV(13, 27). Motavizumab, an affinity-matured derivative of palivizumab,
234 which was not approved for prophylactic use, was assessed as a parenterally administered
235 therapeutic following RSV infection. However, there is conflicting data on motavizumab
236 efficacy, with one study indicating a reduction in viral load(28) and another showing no effect on
237 viral load, clinical severity or length of hospitalisation(32). In pre-clinical studies motavizumab
238 and ALX-0171 was 16.8 fold (33) and 126 fold (26)more potent, respectively, than palivizumab.
239 Studies of G-specific antibodies administered post infection have shown a reduction in
240 inflammation in a mouse model of RSV infection(34, 35). This indicates that there is potential
241 for a monoclonal antibody to be used as an effective treatment for RSV, provided the IC_{50} is
242 sufficient. Route of administration is an important consideration. In a study of an adenovirus-
243 based RSV vaccine, intranasal, but not intramuscular, administration elicited strong IgA
244 responses(36). Both palivizumab and motavizumab were administered intramuscularly, whereas
245 ALX-0171 is inhaled. It is likely, therefore that both the increased IC_{50} values and the routes of

administration may explain why ALX-0171 appears to have greater therapeutic efficacy *in vivo* than previously developed anti-RSV antibodies.

The determinants of RSV disease severity remain unclear and may involve multiple factors, including viral load, viral strain and host susceptibility. It is also thought that the immune response to RSV infection plays a major role in the severity of disease. High viral titers are associated with higher levels of pro-inflammatory cytokines(14, 37). It has been theorised that a higher viral load may indirectly lead to more severe disease due to an excessive immune response involving production of pro-inflammatory cytokines, leukocyte recruitment and subsequent epithelial cell damage(38, 39). This would correlate with the data from the neonatal lamb model, which showed that reduced clinical severity scores were reflective of reduced viral titers. However, there are other studies that show no correlation between viral load and disease severity(40). It is likely that a combination of host and viral factors contribute to the overall severity of disease.

Interestingly, the neonatal lamb model also resulted in a smaller reduction in virus copy numbers in the airways compared to viral titers following ALX-0171 treatment, despite a significant reduction in clinical severity scores(27). This suggests that the viable virus titer is more indicative of disease severity than the viral load detected by RT-qPCR. Although viral load has been correlated with disease severity in both the human challenge model and infants hospitalised with RSV(41, 42), it may be more appropriate to measure replication competent virus as an indicator of disease severity.

The development of RSV pharmaceuticals presents several challenges. These challenges relate primarily to the fact that much of the pathology associated with RSV infection is thought to be

caused by the inflammatory immune responses to the virus infection, rather than direct viral cytopathogenesis. It is imperative, therefore, that RSV antivirals result in both virus neutralisation and modulation of the pro-inflammatory immune responses induced by infection. As has been demonstrated for influenza virus antivirals, such as oseltamivir, early treatment with potent RSV antivirals delivered at sufficiently high doses to the site of infection is likely to be required for effective disease therapy. Using the WD-PBEC model to preform pre-clinical and dose adjustment studies on antiviral treatments offers several benefits. The costs associated with large animal *in vivo* studies is very high and, although WD-PBECs are more expensive than monolayer cell line assays, they can be cultured in a routine class II safety laboratory. Several parameters can be tested in parallel with WD-PBECs and experiments can be carried out in duplicate on cultures from multiple donors. Furthermore, ethical considerations for the use of the neonatal lamb model must include a comprehensive rationale for numbers of animals to be used.

The translation of pre-clinical model data to the clinic has so far proved elusive for RSV therapeutic drugs. The similarity between our RSV/WD-PBEC and the neonatal lamb RSV infection model data suggests that use of our morphologically- and physiologically-authentic RSV/WD-PBEC therapeutic model may provide a basis for predicting drug efficacy in clinical trials that is currently not possible. As such, ALX-0171 may have therapeutic potential against RSV in young infants and our data supports further clinical development.

Materials and Methods

Well-differentiated primary pediatric bronchial cell culture

The generation of WD-PBEC cultures was described previously(20). Briefly, primary pediatric epithelial cells obtained from Lonza were expanded in collagen-coated flasks until almost

confluent and transferred onto collagen-coated semi-permeable (6 mm diameter, 0.4 μ m pore size) Transwells (Corning). When confluent, the apical medium was removed and an air-liquid interface (ALI) was established to promote differentiation. Cells were maintained in ALI for a minimum of 21 days. Cultures were only used when hallmarks of excellent differentiation were evident, including, no holes in the cultures, extensive coverage of beating cilia and obvious mucus production.

Cell lines and viruses

RSV BT2a was originally isolated from a 4-month old infant hospitalized with bronchiolitis in Belfast, UK. It was cultured in HEp-2 cells as previously described(43) and passaged a total of three times before use. RSV Memphis 37 was originally isolated from a four-month old male in Memphis, USA who presented with bronchiolitis. The virus was isolated and passaged in FDA-approved Vero cell cultures as previously described(44). RSV Memphis 37 was further passaged seven times on HEp-2 cells. RSV titers in biological samples were determined by a tissue culture infectious dose 50 (TCID₅₀) assay, as previously described (45), or by RT-qPCR (see below).

Infection and treatment

WD-PBECs were infected apically in duplicate (2 wells per condition per patient) for 2 h at 37°C. Apical rinses were carried out by adding low glucose DMEM and gently pipetted up and down several times. The recovered DMEM was added to cryovials and snap frozen and stored in liquid nitrogen. Following the 24 hpi apical wash the cultures were treated apically with 100 μ L of either ALX-0171 or palivizumab at the indicated concentrations, or buffer control, for 1 h at 37°C. To maintain the air-liquid interface, the treatment was removed and replaced with 10 μ L of the same concentration of ALX-0171 or palivizumab and incubated for 24 h, until the next apical

rinse. After each subsequent apical rinse 10 μ L of the indicated concentration of ALX-0171 or palivizumab were added to the apical surface. This was repeated every 24 h for 6 days.

Virus Quantification

RSV titers in apical washes were determined on HEp-2 cells as previously described(45). To determine the viral load by RT-qPCR RNA was extracted from apical washes (High Pure Viral RNA kit, Roche). cDNA was prepared using 10 μ L RNA (High Capacity cDNA Reverse Transcription kit, ABI). The Light Cycler 480 probe master kit (Roche) was used to amplify RSV cDNA. Primers and probes specific for RSV L-gene were designed with Mega6 software based on alignment of multiple RSV L-gene sequences derived from GenBank representing both clinical and prototypic strains of RSV A and B subgroups (Table 2). Standard curves were generated using a plasmid containing the RSV-A2 genome in 10-fold dilutions.

Statistical Analysis

. The change in TCID₅₀ values over time was summarized per donor using the area under the curve (AUC) for each compound and concentration. Area under the viral load curves (AUC) were computed using the trapezoid rule in Graphpad Prism where the lower limit of detection of TCID₅₀ was used as a baseline for calculation. Subsequently, the dose response of average AUC values was fitted using a 4PL with the bottom constrained to 0 to calculate the IC₅₀ values. Since the variances were not assumed to be equal, a Welch's t-test was performed and the degrees of freedom were approximated using the Welch-Satterthwaite equation. Two-sided t-tests were performed at a 5% significance level based on the IC₅₀ from the 4PL model.

334

335 **Acknowledgements.**

336 This study was wholly funded by Alynx, Belgium, in a research project conducted at Queen's
337 University Belfast.

338 **References.**

339

- 340 1. Afonso CL, Amarasinghe GK, Bányai K, Bào Y, Basler CF, Bavari S, Bejerman N,
341 Blasdel KR, Briand F-X, Briesse T, Bukreyev A, Calisher CH, Chandran K, Chéng J,
342 Clawson AN, Collins PL, Dietzgen RG, Dolnik O, Domier LL, Dürrwald R, Dye JM,
343 Easton AJ, Ebihara H, Farkas SL, Freitas-Astúa J, Formenty P, Fouchier RAM, Fù Y,
344 Ghedin E, Goodin MM, Hewson R, Horie M, Hyndman TH, Jiāng D, Kitajima EW,
345 Kobinger GP, Kondo H, Kurath G, Lamb RA, Lenardon S, Leroy EM, Li C-X, Lin X-D,
346 Liú L, Longdon B, Marton S, Maisner A, Mühlberger E, Netesov S V., Nowotny N,
347 Patterson JL, Payne SL, Paweska JT, Randall RE, Rima BK, Rota P, Rubbenstroth D,
348 Schwemmle M, Shi M, Smither SJ, Stenglein MD, Stone DM, Takada A, Terregino C,
349 Tesh RB, Tian J-H, Tomonaga K, Tordo N, Towner JS, Vasilakis N, Verbeek M,
350 Volchkov VE, Wahl-Jensen V, Walsh JA, Walker PJ, Wang D, Wang L-F, Wetzel T,
351 Whitfield AE, Xiè J, Yuen K-Y, Zhang Y-Z, Kuhn JH. 2016. Taxonomy of the order
352 Mononegavirales: update 2016. Arch Virol 161:2351–2360.
- 353 2. Staat MA. 2002. Respiratory syncytial virus infections in children. Semin Respir Infect
354 17:15–20.

- 355 3. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P,
356 Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden
357 of respiratory syncytial virus infection in young children. *N Engl J Med* 360:588–98.
- 358 4. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca
359 A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER,
360 Ngama M, Munywoki PK, Kartasasmita C, Simões EAF, Rudan I, Weber MW, Campbell
361 H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial
362 virus in young children: a systematic review and meta-analysis. *Lancet* 375:1545–55.
- 363 5. Moore HC, Jacoby P, Hogan AB, Blyth CC, Mercer GN. 2014. Modelling the seasonal
364 epidemics of respiratory syncytial virus in young children. *PLoS One* 9:e100422.
- 365 6. Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. 1999. Respiratory syncytial
366 virus stimulates neutrophil degranulation and chemokine release. *J Immunol* 163:2816–
367 20.
- 368 7. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. 1970. Pathological changes in
369 virus infections of the lower respiratory tract in children. *J Clin Pathol* 23:7–18.
- 370 8. Hall CB, Simões EAF, Anderson LJ. 2013. Clinical and epidemiologic features of
371 respiratory syncytial virus. *Curr Top Microbiol Immunol* 372:39–57.
- 372 9. Couch RB, Englund JA, Whimbey E. 1997. Respiratory viral infections in
373 immunocompetent and immunocompromised persons. *Am J Med* 102:2-9; discussion 25–
374 6.
- 375 10. Jha A, Jarvis H, Fraser C, Openshaw PJ. 2016. Respiratory Syncytial Virus SARS, MERS

and other Viral Lung Infections. European Respiratory Society.

11. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, Melero JA. 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. *J Gen Virol* 73:2225–2234.
12. Olchanski N, Hansen RN, Pope E, D’Cruz B, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD. 2018. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. *Open forum Infect Dis* 5:ofy031.
13. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, Buckingham S, Vernacchio L, Ambrosino DM. 1998. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. *J Infect Dis* 178:1555–61.
14. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. 2011. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. *J Infect Dis* 204:996–1002.
15. WHITLEY RJ, HAYDEN FG, REISINGER KS, YOUNG N, DUTKOWSKI R, IPE D, MILLS RG, WARD P. 2001. Oral oseltamivir treatment of influenza in children. *Pediatr Infect Dis J* 20:127–133.
16. McLean HQ, Belongia EA, Kieke BA, Meece JK, Fry AM. 2015. Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a

397 Randomized Trial. *Open Forum Infect Dis* 2.

398 17. Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, Yusuf M, Kapur
399 P, Hardy RD, Hatfield J, Rogers BB, Krisher K, Ramilo O. 2004. Respiratory syncytial
400 virus induces pneumonia, cytokine response, airway obstruction, and chronic
401 inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. *J*
402 *Infect Dis* 189:1856–65.

403 18. Plotnicky-Gilquin H, Huss T, Aubry JP, Haeuw JF, Beck A, Bonnefoy JY, Nguyen TN,
404 Power UF. 1999. Absence of lung immunopathology following respiratory syncytial virus
405 (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.
406 *Virology* 258:128–40.

407 19. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN. 2001.
408 Differential histopathology and chemokine gene expression in lung tissues following
409 respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-
410 immunized mice. *J Virol* 75:12421–30.

411 20. Broadbent L, Villenave R, Guo-Parke H, Douglas I, Shields MD, Power UF. 2016. In
412 Vitro Modeling of RSV Infection and Cytopathogenesis in Well-Differentiated Human
413 Primary Airway Epithelial Cells (WD-PAECs)., p. 119–39. *In Methods in molecular*
414 *biology* (Clifton, N.J.).

415 21. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG,
416 McKaigue JP, Coyle P V, Shields MD, Power UF. 2012. In vitro modeling of respiratory
417 syncytial virus infection of pediatric bronchial epithelium, the primary target of infection
418 in vivo. *Proc Natl Acad Sci U S A* 109:5040–5.

- 419 22. Guo-Parke H, Canning P, Douglas I, Villenave R, Heaney LG, Coyle P V, Lyons JD,
420 Shields MD, Power UF. 2013. Relative respiratory syncytial virus cytopathogenesis in
421 upper and lower respiratory tract epithelium. *Am J Respir Crit Care Med* 188:842–51.
- 422 23. Johnson SM, McNally BA, Ioannidis I, Flano E, Teng MN, Oomens AG, Walsh EE,
423 Peeples ME. 2015. Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary
424 Human Airway Epithelial Cultures. *PLOS Pathog* 11:e1005318.
- 425 24. Cortjens B, Yasuda E, Yu X, Wagner K, Claassen YB, Bakker AQ, van Woensel JBM,
426 Beaumont T. 2017. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from
427 Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells. *J*
428 *Virol* 91.
- 429 25. Broadbent L, Groves H, Shields MD, Power UF. 2015. RSV, an on-going medical
430 dilemma: an expert commentary on RSV prophylactic and therapeutic pharmaceuticals
431 currently in clinical trials. *Influenza Other Respi Viruses*.
- 432 26. Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF,
433 Stortelers C, Allosery K, Melero JA, Depla E. 2016. Generation and Characterization of
434 ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory
435 Syncytial Virus Infection. *Antimicrob Agents Chemother* 60:6–13.
- 436 27. Larios Mora A, Detalle L, Gallup JM, Van Geelen A, Stohr T, Duprez L, Ackermann MR.
437 2018. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus
438 disease in newborn lambs. *MAbs* 10:778–795.
- 439 28. Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.

2009. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. *Pediatr Infect Dis J* 28:835–7.

29. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, Aitken JA, Patel A, DeVincenzo JP. 2005. Comparison of a Real-Time Reverse Transcriptase PCR Assay and a Culture Technique for Quantitative Assessment of Viral Load in Children Naturally Infected with Respiratory Syncytial Virus. *J Clin Microbiol* 43:2356–2362.

30. Scheerlinck J-PY, Snibson KJ, Bowles VM, Sutton P. 2008. Biomedical applications of sheep models: from asthma to vaccines. *Trends Biotechnol* 26:259–66.

31. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. *J Virol* 76:5654–66.

32. Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP. 2014. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. *Pediatr Infect Dis J* 33:703–9.

33. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. 2007. Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract. *J Mol Biol* 368:652–665.

34. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, Anderson LJ. 2009.

Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus
(RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV
Infection in BALB/c Mice. *J Infect Dis* 200:439–447.

35. Caidi H, Miao C, Thornburg NJ, Tripp RA, Anderson LJ, Haynes LM. 2018. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. *Antiviral Res* 154:149–157.
36. Yu J-R, Kim S, Lee J-B, Chang J. 2008. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. *J Virol* 82:2350–7.
37. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. *Am J Respir Crit Care Med* 182:1305–14.
38. Johansson C. 2016. Respiratory syncytial virus infection: an innate perspective. *F1000Research* 5:2898.
39. Goritzka M, Makris S, Kausar F, Durant LR, Pereira C, Kumagai Y, Culley FJ, Mack M, Akira S, Johansson C. 2015. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. *J Exp Med* 212:699–714.

- 482 40. Wright PF, Gruber WC, Peters M, Reed G, Zhu Y, Robinson F, Coleman-Dockery S,
483 Graham BS. 2002. Illness severity, viral shedding, and antibody responses in infants
484 hospitalized with bronchiolitis caused by respiratory syncytial virus. *J Infect Dis*
485 185:1011–8.
- 486 41. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L,
487 Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R,
488 Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans
489 experimentally infected with respiratory syncytial virus. *Am J Respir Crit Care Med*
490 182:1305–14.
- 491 42. DeVincenzo JP, El Saleeby CM, Bush AJ. 2005. Respiratory syncytial virus load predicts
492 disease severity in previously healthy infants. *J Infect Dis* 191:1861–8.
- 493 43. Villenave R, Touzelet O, Thavagnanam S, Sarlang S, Parker J, Skibinski G, Heaney LG,
494 McKaigue JP, Coyle P V, Shields MD, Power UF. 2010. Cytopathogenesis of Sendai
495 virus in well-differentiated primary pediatric bronchial epithelial cells. *J Virol* 84:11718–
496 28.
- 497 44. Kim Y-I, DeVincenzo JP, Jones BG, Rudraraju R, Harrison L, Meyers R, Cehelsky J,
498 Alvarez R, Hurwitz JL. 2014. Respiratory syncytial virus human experimental infection
499 model: provenance, production, and sequence of low-passaged memphis-37 challenge
500 virus. *PLoS One* 9:e113100.
- 501 45. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen
502 TN, Binz H. 1997. Induction of protective immunity in rodents by vaccination with a
503 prokaryotically expressed recombinant fusion protein containing a respiratory syncytial

virus G protein fragment. *Virology* 230:155–166.

Figure 1. Duplicate WD-PBEC cultures (n=3 donors) were infected apically with either RSV BT2a (A) or RSV Memphis 37 (B) (MOI=0.1) for 2 h at 37°C and then washed 5 times. The fifth wash was retained as the 2 hpi time point for virus titrations. At 24 hpi (and every 24 h thereafter) apical washes were undertaken and harvested for virus titrations. Following the apical washes at 24 hpi (and every 24 h thereafter) the cultures were apically treated with 100 µL ALX-0171 at the indicated concentrations. After 1 h the treatment was removed and replaced with 10 µL ALX-0171 at the same concentration, which remained on the apical surfaces for the duration of the interval between washes. All apical washes were titrated on HEp-2 cells to determine viral titers, which were reported as $\log_{10}$ TCID₅₀/mL $\pm$ SEM (LOD = limit of detection).

Figure 2. Duplicate WD-PBEC cultures (n=3 donors) were infected apically with RSV BT2a (A) or RSV Memphis 37 (b) (MOI=0.1) for 2 h at 37°C and then washed 5 times. The fifth wash was retained as the 2 hpi time point for virus titrations. At 24 hpi (and every 24 h thereafter) apical

washes were undertaken and harvested for virus titrations. Following the apical washes at 24 hpi (and every 24 h thereafter) the cultures were apically treated with 100 μ L palivizumab at the indicated concentrations. After 1 h the treatment was removed and replaced with 10 μ L palivizumab at the same concentration, which remained on the apical surfaces for the duration of the intervals between washes. All apical washes were titrated on HEp-2 cells to determine viral titers, which were reported as $\log_{10}$ TCID₅₀/mL $\pm$ SEM. (LOD = limit of detection)

Figure 3. WD-PBEC cultures (n=3 donors and duplicated cultures for each conditions) were infected apically with RSV BT2a (A) or RSV Memphis 37 (B) (MOI=0.1) for 2 h at 37°C and then washed 5 times. The fifth wash was retained as the 2 hpi time point for virus titrations. At 24 hpi (and every 24 h thereafter) apical washes were undertaken and harvested for virus titrations. Following the apical washes at 24 hpi (and every 24 h thereafter) the cultures were apically treated with 100 μ L of either ALX-0171 or palivizumab at the indicated concentrations. After 1 h the treatment was removed and replaced with 10 μ L of either ALX-0171 or palivizumab at the same concentration, which remained on the apical surfaces for the duration of the intervals between washes. All apical washes were titrated on HEp-2 cells to determine viral titers, which were reported as $\log_{10}$ TCID₅₀/mL $\pm$ SEM. (LOD = limit of detection).

Figure 4. WD-PBEC cultures (n=3 donors and duplicated cultures for each conditions) were infected apically with RSV BT2a (A) or RSV Memphis 37 (B) (MOI=0.1) for 2 h at 37°C and then washed 5 times. The fifth wash was retained as the 2 hpi time point. At 24 hpi (and every 24

h thereafter) apical washes were harvested. Following the apical washes at 24 hpi (and every 24 h thereafter) the cultures were apically treated with 100 µL of ALX-0171 or palivizumab at the indicated concentrations. After 1 h the treatment was removed and replaced with 10 µL of either ALX-0171 or palivizumab at the same concentration, which remained on the apical surfaces for the duration of the intervals between washes. RNA was extracted from apical washes and RT-qPCR performed. Data were plotted as $\log_{10}$ genome copies/mL $\pm$ SEM.

Table 1: IC₅₀ for ALX-0171 and palivizumab towards RSV BT2a or RSV Memphis 37

RSV Memphis 37	IC₅₀* [95% Confidence Intervals] in nM
ALX-0171	363.6 [276.3-472.9]
Palivizumab	1090 [727.2-2126]
P-value (palivizumab v ALX)	0.0038
RSV BT2a	IC₅₀* [95% Confidence Intervals] in nM

ALX-0171	346.9 [262.2-468.3]
Palivizumab	1048 [869-1337]
P-value (palivizumab v ALX)	0.0001

564

565

566

567 **Table 2: RT-qPCR primer and probe sequences**

Forward primer 3 5'- GATTGCAATGATCATAGTTTACC			
Reverse			
hRSV	Primer	4	5'- TAAANTTTGCNGAACCTATNAG
L-gene	degenerate		
Hydrolysis			
			5'- GACCATTCCTGCTACAGATG
	Probe 12		

568

569

570